journal article·2024-12Open access

A Study on Overcoming Post‐TACE Drug Resistance in HCC Based on Controllable Oxygen Release‐Magnetic Hyperthermia Therapy

Jin‐Xin Huang, Wei‐Hua Zhang, Ye‐Ming Wu, Jian‐Yu Hu, Huan Long, Hai‐Dong Zhu, Jian‐Qiong Zhang, Gao‐Jun Teng, Fei Xiong

Advanced Healthcare Materials· Volume 13· Issue 32

Abstract

Abstract Drug‐eluting bead transcatheter arterial chemoembolization (D‐TACE) is one of the first‐line treatment for intermediate hepatocellular carcinoma (HCC). However, the dual hypoxia microenvironment, due to inherent tumor hypoxia and TACE‐induced hypoxia, triggers drug resistance in HCC. To address this challenge, the study develops multicavitary microspheres capable of encapsulating oxygen and harnessing magnetic hyperthermia to enhance oxygen permeability. The novel multicavitary oxygen‐encapsulated magnetothermal drug‐eluting microspheres (OTD‐Ms) effectively reduce hypoxia‐related proteins (HIF‐1α, VEGF‐A) and drug resistance (P‐gp) both in vitro and in vivo. Moreover, these microspheres demonstrate improved TACE efficacy and enhance survival rates in a rabbit VX‐2 tumor model, suggesting their potential for HCC treatment.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Hepatocellular Carcinoma Treatment and Prognosis · Cancer, Hypoxia, and Metabolism

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Digital Medical Engineering Jiangsu Key Laboratory for Biomaterials and Devices School of Biological Sciences & Medical Engineering Southeast University Nanjing 210009 P. R. China

Center of Interventional Radiology and Vascular Surgery Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University) Department of Radiology, Zhongda Hospital, Medical School Southeast University 87 Dingjiaqiao Road Nanjing 210009 P. R. China

National Innovation Platform for Integration of Medical Engineering Education (NMEE) (Southeast University) Nanjing 210009 P. R. China

Basic Medicine Research and Innovation Center of Ministry of Education Zhongda Hospital Southeast University Nanjing 210009 P. R. China

Department of Radiology Zhongda Hospital Medical School Southeast University 87 Dingjiaqiao Road Nanjing 210009 P. R. China

Department of Pharmacy Zhongda Hospital School of Medicine Southeast University Nanjing 210009 P. R. China

Department of Microbiology and Immunology School of Medicine Southeast University Nanjing 210009 P. R. China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China

References (46)

Show source-provided references
1. 10.3322/caac.2149210.3322/caac.21492 ↗
2. 10.1111/liv.1513010.1111/liv.15130 ↗
3. 10.1148/radiol.1111014410.1148/radiol.11110144 ↗
4. 10.1055/s-0033-133364810.1055/s-0033-1333648 ↗
5. 10.1007/s00270-007-9280-610.1007/s00270-007-9280-6 ↗
6. 10.1001/jamaoncol.2015.218910.1001/jamaoncol.2015.2189 ↗
7. 10.1016/j.jhep.2021.11.01810.1016/j.jhep.2021.11.018 ↗
8. 10.14740/jocmr2496w10.14740/jocmr2496w ↗
9. 10.1111/j.1440-1746.2007.04997.x10.1111/j.1440-1746.2007.04997.x ↗
10. 10.1016/j.critrevonc.2010.10.00510.1016/j.critrevonc.2010.10.005 ↗
11. 10.1586/14737140.8.10.162310.1586/14737140.8.10.1623 ↗
12. 10.2217/fon-2017-073910.2217/fon-2017-0739 ↗
13. 10.1080/10717544.2022.208138410.1080/10717544.2022.2081384 ↗
14. 10.1007/s00270-006-0062-310.1007/s00270-006-0062-3 ↗
15. 10.3748/wjg.v20.i12.306910.3748/wjg.v20.i12.3069 ↗
16. 10.1177/205064061667351610.1177/2050640616673516 ↗
17. 10.3390/cancers1423584710.3390/cancers14235847 ↗
18. 10.1002/advs.20230127810.1002/advs.202301278 ↗
19. 10.1016/j.nantod.2023.10176710.1016/j.nantod.2023.101767 ↗
20. 10.1016/j.nantod.2022.10145810.1016/j.nantod.2022.101458 ↗
21. 10.3109/1073119940913880110.3109/10731199409138801 ↗
22. 10.1007/s00424-020-02482-210.1007/s00424-020-02482-2 ↗
23. 10.1016/j.coph.2020.08.01010.1016/j.coph.2020.08.010 ↗
24. 10.1016/j.blre.2022.10092710.1016/j.blre.2022.100927 ↗
25. 10.1097/MAT.000000000000201710.1097/MAT.0000000000002017 ↗
26. 10.1021/acs.molpharmaceut.3c0011610.1021/acs.molpharmaceut.3c00116 ↗
27. 10.3389/fbioe.2023.111525410.3389/fbioe.2023.1115254 ↗
28. 10.1080/10408347.2021.200746910.1080/10408347.2021.2007469 ↗
29. 10.1016/j.breast.2011.12.01210.1016/j.breast.2011.12.012 ↗
30. 10.1016/j.critrevonc.2016.04.00110.1016/j.critrevonc.2016.04.001 ↗
31. 10.4103/jcrt.JCRT_1261_1610.4103/jcrt.JCRT_1261_16 ↗
32. 10.1021/acsami.7b1433010.1021/acsami.7b14330 ↗
33. 10.1016/j.actbio.2022.09.05410.1016/j.actbio.2022.09.054 ↗
34. 10.1016/j.ijbiomac.2019.10.02610.1016/j.ijbiomac.2019.10.026 ↗
35. 10.1016/j.jmbbm.2011.08.00110.1016/j.jmbbm.2011.08.001 ↗
36. 10.1007/s10856-006-0592-x10.1007/s10856-006-0592-x ↗
37. 10.1016/j.jmbbm.2010.05.00410.1016/j.jmbbm.2010.05.004 ↗
38. 10.1007/s10856-007-3068-810.1007/s10856-007-3068-8 ↗
39. 10.1097/01.RVI.0000195323.46152.B310.1097/01.RVI.0000195323.46152.B3 ↗
40. 10.1007/s00270-015-1057-810.1007/s00270-015-1057-8 ↗
41. Lu E. · Cancer Biother. Radio. · 2023 · 38 · 641
42. 10.1016/j.jvir.2018.12.02210.1016/j.jvir.2018.12.022 ↗
43. 10.1177/107815521559441610.1177/1078155215594416 ↗
44. 10.1016/j.xphs.2016.08.01110.1016/j.xphs.2016.08.011 ↗
45. 10.1136/ejhpharm-2015-00066810.1136/ejhpharm-2015-000668 ↗
46. 10.1016/j.jvir.2010.02.04210.1016/j.jvir.2010.02.042 ↗